Timmins, P., III, Kredentser, D., Hancock, K., Messing, M., Boehm, K.A., Mull, S., & Asmar, L. (2008). Results of an open-label study to evaluate the efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with carboplatin-containing chemotherapy in patients with ovarian cancer, primary peritoneal, or fallopian tube carcinoma (stage I–IV) or papillary serous cancer of the uterus. Clinical Ovarian Cancer, 1, 60–65.
To evaluate the effectiveness of the combination of palonosetron, aprepitant, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting (CINV)
In cycle 1 of chemotherapy, safety and efficacy was assessed. In subsequent cycles, assessment of nausea was emphasized. Actual dosage and schedule of medications was not described. Patients completed Functional Living Index-Emesis (FLIE) scores at various time points in the study; however, these specific time points were not stated.
All patients were in active treatment.
This was a prospective, open-label trial.
The combination of drugs used appeared to be well tolerated. Firm conclusions regarding efficacy cannot be drawn.
This study provides some evidence that combinations of palonosetron, aprepitant, and dexamethasone can be well tolerated.